Clicky

IDEAYA BIOSCIENCE DL-01(30J)

Description: IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.


Keywords: Cancer Solid Tumors Drug Discovery Tumor Genetics Deficiency Recombination Synthetic Lethality Homologous Recombination

Home Page: www.ideayabio.com

7000 Shoreline Court
South San Francisco, CA 94080
United States
Phone: 650 443 6209


Officers

Name Title
Mr. Yujiro S. Hata President, CEO & Director
Mr. Andres Ruiz Briseno CPA Principal Accounting Officer, Senior VP and Head of Finance & Investor Relations
Dr. Michael A. White Ph.D. Chief Scientific Officer
Dr. Darrin M. Beaupre M.D., Ph.D. Chief Medical Officer
Dr. Paul A. Barsanti Ph.D. Chief Technology Officer
Mr. Douglas B. Snyder Senior VP & General Counsel
Ms. Francine Zelaya Vice President & Head of Human Resources
Mr. Mick O'Quigley Chief of Staff & Clinical Development
Mr. Daniel A. Simon Chief Business Officer
Mr. Stuart Dorman Chief Commercial Officer

Exchange: F

Country: DE : Germany

Currency: Euro (€)

Forward PE: 9.4877
Trailing PE: 0
Price-to-Book MRQ: 1.9222
Price-to-Sales TTM: 552.8268
IPO Date:
Fiscal Year End: December
Full Time Employees: 124
Back to stocks